Wanlin Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wanlin Cui has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bitian Liu
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
1 shared publication Chang Liu
Department of Pediatrics, The First Hospital of China Medical University
1 shared publicationHaitao Chu
Department of Hyperbaric Oxygen Medicine, The First Hospital of China Medical University
1 shared publicationHehe Zhu
Department of Urology, Shengjing Hospital of China Medical University
1 shared publicationJiaman Lin
Department of Urology, Shengjing Hospital of China Medical University
1 shared publicationRui Yin
Department of Urology, Shengjing Hospital of China Medical University
1 shared publication
Latest Publications
- Open Access
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1870619
Gut microbial bile salt hydrolase as a metabolic gatekeeper in digestive homeostasis and disease
The gut microbiota exerts broad control over host physiology through tightly coordinated metabolic networks. Among these, bile salt hydrolase (BSH), a microbial enzyme, serves as a key mediator of microbiota–host crosstalk. As a key upstream gateway reaction in bile acid metabolism, BSH hydrolyzes conjugated bile acids and reshapes the composition and distribution of the intestinal bile acid pool. This remodeling alters bile acid signaling quality and influences the host energy metabolism, immune homeostasis and intestinal barrier integrity. In this review, we summarize the core biological functions and molecular regulatory mechanisms of microbial BSH in maintaining digestive system homeostasis. We further discuss the association between BSH dysregulation and the development of major digestive diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD), inflammatory bowel disease (IBD) and colorectal cancer (CRC). Finally, we outline emerging precision strategies targeting BSH, including strain-specific probiotics, enzyme activity modulators and dietary interventions. These approaches offer a conceptual framework for microbiota-based therapies in digestive diseases.
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1870619
Open AccessGut microbial bile salt hydrolase as a metabolic gatekeeper in digestive homeostasis and disease
The gut microbiota exerts broad control over host physiology through tightly coordinated metabolic networks. Among these, bile salt hydrolase (BSH), a microbial enzyme, serves as a key mediator of microbiota–host crosstalk. As a key upstream gateway reaction in bile acid metabolism, BSH hydrolyzes conjugated bile acids and reshapes the composition and distribution of the intestinal bile acid pool. This remodeling alters bile acid signaling quality and influences the host energy metabolism, immune homeostasis and intestinal barrier integrity. In this review, we summarize the core biological functions and molecular regulatory mechanisms of microbial BSH in maintaining digestive system homeostasis. We further discuss the association between BSH dysregulation and the development of major digestive diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD), inflammatory bowel disease (IBD) and colorectal cancer (CRC). Finally, we outline emerging precision strategies targeting BSH, including strain-specific probiotics, enzyme activity modulators and dietary interventions. These approaches offer a conceptual framework for microbiota-based therapies in digestive diseases.
- Open Access
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1727550
Carcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention
Bladder cancer remains a significant global health concern, with environmental carcinogen exposure—particularly from tobacco-derived compounds such as aromatic amines, polycyclic aromatic hydrocarbons (PAHs), and nitrosamines—recognized as a primary etiological factor. These carcinogens undergo complex metabolic activation in the liver, bladder epithelium, and gut microbiota, generating reactive intermediates that initiate DNA damage, oxidative stress, and pro-tumorigenic signaling. This review synthesizes emerging evidence on how carcinogen-induced metabolic reprogramming contributes to bladder cancer initiation and progression, emphasizing the roles of key genetic pathways and metabolic enzymes involved in xenobiotic detoxification, DNA repair, and redox regulation. In parallel, we examine the influence of gut microbiota on carcinogen bioactivation and biotransformation, highlighting its dual role as both a metabolic modulator and a potential preventive target. We critically evaluate human observational data linking microbiome dysbiosis to bladder cancer risk, while addressing limitations such as small cohort sizes and confounders like diet and age. Finally, we discuss promising strategies for risk mitigation, including microbiome-directed interventions, dietary modulation, and chemopreventive agents that counteract carcinogenic effects. By integrating molecular oncology, toxicogenomics, and host-microbiome interactions, this review provides a mechanistic framework for understanding bladder cancer etiology and identifies novel opportunities for preventive and precision interventions.
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 15, 1727550
Open AccessCarcinogen metabolism and bladder cancer: role of gut microbiota in disease and prevention
Bladder cancer remains a significant global health concern, with environmental carcinogen exposure—particularly from tobacco-derived compounds such as aromatic amines, polycyclic aromatic hydrocarbons (PAHs), and nitrosamines—recognized as a primary etiological factor. These carcinogens undergo complex metabolic activation in the liver, bladder epithelium, and gut microbiota, generating reactive intermediates that initiate DNA damage, oxidative stress, and pro-tumorigenic signaling. This review synthesizes emerging evidence on how carcinogen-induced metabolic reprogramming contributes to bladder cancer initiation and progression, emphasizing the roles of key genetic pathways and metabolic enzymes involved in xenobiotic detoxification, DNA repair, and redox regulation. In parallel, we examine the influence of gut microbiota on carcinogen bioactivation and biotransformation, highlighting its dual role as both a metabolic modulator and a potential preventive target. We critically evaluate human observational data linking microbiome dysbiosis to bladder cancer risk, while addressing limitations such as small cohort sizes and confounders like diet and age. Finally, we discuss promising strategies for risk mitigation, including microbiome-directed interventions, dietary modulation, and chemopreventive agents that counteract carcinogenic effects. By integrating molecular oncology, toxicogenomics, and host-microbiome interactions, this review provides a mechanistic framework for understanding bladder cancer etiology and identifies novel opportunities for preventive and precision interventions.
- 16 October 2024
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 8 (11) , e16
Home phototherapy: an essential component of managing hyperbilirubinaemia
- 16 October 2024
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 8 (11) , e16
Home phototherapy: an essential component of managing hyperbilirubinaemia